Article Versions Notes

Thoueille P, Alves Saldanha S, Schaller F, Munting A, Cavassini M, Braun D, Günthard HF, Kusejko K, Surial B, Furrer H, et al. Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland. Pharmaceutics. 2022; 14(8):1588. https://doi.org/10.3390/pharmaceutics14081588

Thoueille, Paul, Susana Alves Saldanha, Fabian Schaller, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, and et al. 2022. "Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland" Pharmaceutics 14, no. 8: 1588. https://doi.org/10.3390/pharmaceutics14081588

Thoueille, P., Alves Saldanha, S., Schaller, F., Munting, A., Cavassini, M., Braun, D., Günthard, H. F., Kusejko, K., Surial, B., Furrer, H., Rauch, A., Ustero, P., Calmy, A., Stoeckle, M., Battegay, M., Marzolini, C., Andre, P., Guidi, M., Buclin, T., ... on behalf of the Swiss HIV Cohort Study. (2022). Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland. Pharmaceutics, 14(8), 1588. https://doi.org/10.3390/pharmaceutics14081588